CCR5 expression influences the progression of human breast cancer in a p53-dependent manner

被引:122
作者
Mañes, S
Mira, E
Colomer, R
Montero, S
Real, LM
Gómez-Moutón, C
Jiménez-Baranda, S
Garzón, A
Lacalle, RA
Harshman, K
Ruíz, A
Martínez, C
机构
[1] Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain
[2] Univ Madrid, Hosp 12 Octubre, Dept Pathol, E-28041 Madrid, Spain
[3] Neocodex, Dept Struct Genom, E-41020 Seville, Spain
关键词
chemokine receptor; breast cancer; p53; CCR5; polymorphism; p38;
D O I
10.1084/jem.20030580
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chemokines are implicated in tumor pathogenesis, although it is unclear whether they affect human cancer progression positively or negatively. We found that activation of the chemokine receptor CCR5 regulates p53 transcriptional activity in breast cancer cells through pertussis toxin-, JAK2-, and p38 mitogen-activated protein kinase-dependent mechanisms. CCR5 blockade significantly enhanced proliferation of xenografts from tumor cells bearing wild-type p53, but did not affect proliferation of tumor xenografts bearing a p53 mutation. In parallel, data obtained in a primary breast cancer clinical series showed that disease-free survival was shorter in individuals bearing the CCR5A32 allele than in CCR5 wild-type patients, but only for those whose tumors expressed wild-type p53. These findings suggest that CCR5 activity influences human breast cancer progression in a p53-dependent manner.
引用
收藏
页码:1381 / 1389
页数:9
相关论文
共 39 条
[31]   Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene [J].
Samson, M ;
Libert, F ;
Doranz, BJ ;
Rucker, J ;
Liesnard, C ;
Farber, CM ;
Saragosti, S ;
Lapoumeroulie, C ;
Cognaux, J ;
Forceille, C ;
Muyldermans, G ;
Verhofstede, C ;
Burtonboy, G ;
Georges, M ;
Imai, T ;
Rana, S ;
Yi, YJ ;
Smyth, RJ ;
Collman, RG ;
Doms, RW ;
Vassart, G ;
Parmentier, M .
NATURE, 1996, 382 (6593) :722-725
[32]  
Sanchez-Prieto R, 2000, CANCER RES, V60, P2464
[33]   CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis [J].
Sellebjerg, F ;
Madsen, HO ;
Jensen, CV ;
Jensen, J ;
Garred, P .
JOURNAL OF NEUROIMMUNOLOGY, 2000, 102 (01) :98-106
[34]   Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16(INK4a) [J].
Serrano, M ;
Lin, AW ;
McCurrach, ME ;
Beach, D ;
Lowe, SW .
CELL, 1997, 88 (05) :593-602
[35]  
Taichman RS, 2002, CANCER RES, V62, P1832
[36]  
Taub DD, 1996, J IMMUNOL, V156, P2095
[37]   RANTES activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells [J].
Wong, M ;
Uddin, S ;
Majchrzak, B ;
Huynh, T ;
Proudfoot, AEI ;
Platanias, LC ;
Fish, EN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (14) :11427-11431
[38]   Regulation of p53 function [J].
Woods, DB ;
Vousden, KH .
EXPERIMENTAL CELL RESEARCH, 2001, 264 (01) :56-66
[39]   CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis [J].
Zapico, I ;
Coto, E ;
Rodríguez, A ;
Alvarez, C ;
Torre, JC ;
Alvarez, V .
GENES AND IMMUNITY, 2000, 1 (04) :288-289